Abstracts tagged "registry"

Abstract Number: 0454 • ACR Convergence 2020
Anticytokine Therapies for Inflammatory Rheumatic Disease (IRD) Are Associated with Reduced Hospitalisation Following Community COVID-19 Infection; Results of the Trinity Rheumatology and Covid-19 Registry – TRACR
Rachael Flood¹, Richard Conway², David Kane¹ and Ronan Mullan¹, ¹Tallaght University Hospital, Dublin, Ireland, ²St James's Hospital, Dublin, Ireland
Background/Purpose: Anticytokine biological disease modifying anti-rheumatic drugs (bDMARD), which are widely prescribed for Inflammatory Rheumatological Diseases (IRD) are currently undergoing clinical trials for the treatment…
Abstract Number: 1029 • ACR Convergence 2020
Clinical Characteristics of Patients with Axial Spondyloarthritis in China: Results from the ChinaAS Registry
Jinmei Su¹, Runsheng Wang², Ping Zhu³, Yanhong Wang⁴, Shangzhu Zhang¹, Linyi Peng¹, Min Yang⁵, Ling Lei⁶, Li Qin⁷, Mengtao Li⁸ and Xiaofeng Zeng⁸, ¹Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China (People's Republic), ²Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ³Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), ⁴Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁵Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (People's Republic), ⁶Department of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ⁷Department of Rheumatology, The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), ⁸Peking Union Medical College Hospital, Department of Rheumatology, Beijing, Beijing, China (People's Republic)
Background/Purpose: The ChinaAS is a nationwide, multicenter registry of patients with axial spondyloarthritis (SpA) in China to facilitate research in epidemiology, pathogenesis, diagnosis and treatment…
Abstract Number: 0601 • ACR Convergence 2020
The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases
Kent Kwas Huston¹, Simon Helfgott², Scott Milligan³, Jasvinder Singh⁴, Nehad Soloman⁵, Brandon Weil³ and Colin Edgerton⁶, ¹Kansas City Physician Partners, Kansas City, MO, ²BWH- HMS, Boston, MA, ³Trio Health, Louisville, CO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Persistence on therapy is an important consideration in rheumatic diseases. There are multiple treatment options that influence long term disease management and a better…
Abstract Number: 1142 • ACR Convergence 2020
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Rebecca Overbury¹, Tracy Frech², John Bohnsack³, CJ Inman¹, Sara Stern¹, Karen James¹, Erin Treemarcki⁴ and Aimee Hersh⁴, ¹University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ³University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁴University of Utah and Primary Children's Hospital, Salt Lake City
Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…
Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Daniel J Lovell¹, Nikolay Tzaribachev², Esi Morgan³, Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Daniel Kietz¹⁵, Ilonka Orban¹⁶, Jason Dare¹⁷, Ivan Foeldvari¹⁸, Pierre Quartier¹⁹, Alyssa Dominique²⁰, Tzuyung Douglas Kou²⁰, Robert Wong²⁰, Alberto Martini²¹, Hermine Brunner³ and Nicolino Ruperto²², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵Children’s Hospital of Pittsburgh, Pittsburgh, PA, ¹⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁷University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁸Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁹Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ²⁰Bristol-Myers Squibb Company, Princeton, NJ, ²¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²²Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
Abstract Number: 1153 • ACR Convergence 2020
Trends in Timing of Biologic Use for Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry
Ginger Janow¹, Timothy Beukelman², Yukiko Kimura³, Rayfel Schneider⁴, Shalini Mohan⁵, Gail Rodich⁶ and Mary Beth Son⁷, ¹Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ, ²University of Alabama at Birmingham, Birmingham, AL, ³Hackensack Meridian School of Medicine, Hackensack, NJ, ⁴University of Toronto, The Hospital for Sick Children, Toronto, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Mill Valley, CA, ⁷Boston Children's Hospital, Boston, MA
Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes. There may…
Abstract Number: 0716 • ACR Convergence 2020
Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study
Ruud Verstegen¹, Peter Shrader², Stephen Balevic³, Timothy Beukelman⁴, Colleen Correll⁵, Anne Dennos⁶, Thomas Phillips² and Brian Feldman¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Duke University, Durham, ³Duke University Medical Center, Durham, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Minnesota, Minneapolis, MN, ⁶Duke University, Durham, NC
Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…
Abstract Number: 1155 • ACR Convergence 2020
Long-term Safety Profile of Anakinra in Patients with Systemic Juvenile Idiopathic Arthritis
Gabriella Giancane¹, Riccardo Papa¹, Sebastiaan Vastert², Francesca Bagnasco¹, Joost Swart¹, Pierre Quartier³, Jordi Anton⁴, Isabelle Kone Paut¹, Sylvia Kamphuis¹, Troels Herlin⁵, Helga Sanner¹, Fabrizio De Benedetti⁶, Elena Tsitsami⁷, Susan Mary Nielsen¹, Estefania Moreno¹, Chiara Pallotti¹, Karin Franck-Larsson⁸, Håkan Malmström⁸, Susanna Cederholm⁹, Nico Wulffraat¹ and Nicolino Ruperto¹⁰, ¹IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, ²University Medical Center Utrecht, Utrecht, Netherlands, ³Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ⁴Sant Joan de Déu Hospital, Madrid, Spain, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁷Aghia Sophia Childrens Hospital, Athens, Greece, ⁸Swedish Orphan Biovitrum, Stockholm, Sweden, ⁹Sobi, Stockholm, Sweden, ¹⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: To evaluate the long-term safety profile of anakinra in patients with systemic juvenile idiopathic arthritis (sJIA)Methods: Data from patients with sJIA according to the…
Abstract Number: 0734 • ACR Convergence 2020
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jordan Jones¹, Chelsey Smith², Daniel J Lovell³ and Mara Becker⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Children's Mercy Kansas City, Holden, MO, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Duke University School of Medicine, Durham, NC
Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…
Abstract Number: 1162 • ACR Convergence 2020
Comparison of Clinicopathologic and Imaging Features Between Chronic Nonbacterial Osteomyelitis and Its Mimickers: A Multi-national 450 Case-Control Study
Yongdong Zhao¹, Raymond Naden², Melissa Oliver³, Zhaoyi Wang⁴, Eveline Wu⁵, Cassyanne Aguiar⁶, Jonathan Akikusa⁷, Ozge Basaran⁸, Kevin Cain¹, Martina Capponi⁹, Nathan Donaldson¹⁰, Emily Fox¹¹, Antonella Insalaco¹², Annette Jansson¹³, Ummusen Kaya Akca¹⁴, Tzielan Lee¹⁵, Edoardo Marrani¹⁶, Kamran Mahmood¹⁷, Elizabeth Murray¹⁸, Farzana Nuruzzaman¹⁹, Karen Onel²⁰, Manuela Pardeo¹², Lauren Potts²¹, Nathan Rogers¹⁰, Anja Schnabel²², Gabriele Simonini²³, Jennifer Soep¹⁰, Sara Stern²⁴, Alexander Theos²⁵, Yujuan Zhang²⁶, Polly Ferguson²⁷, Christian Hedrich²⁸, Fatma Dedeoglu²⁹, Hermann Girschick³⁰, Ronald Laxer³¹ and Seza Ozen³², ¹University of Washington, Seattle, WA, ²Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand, ³Department of Pediatric Rheumatology, Riley Children's Hospital, Carmel, IN, ⁴University of Washington, Bothell, WA, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Children's Hospital of the King's Daughters/EVMS, Norfolk, VA, ⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy, ⁸Hospital for Special Surgery, New York City, NY, ⁹IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ¹⁰Children's Hospital Colorado, Aurora, CO, ¹¹Children's Mercy Kansas City, Kansas City, MO, ¹²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ¹³Dr. von Hauner Children's Hospital, Munich, Germany, ¹⁴Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ¹⁵Stanford University School of Medicine, Palo Alto, CA, ¹⁶University of Florence, Firenze, Italy, ¹⁷Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, England, United Kingdom, ¹⁸CRMO Patient Partner, New York, NY, ¹⁹Stony Brook Children's Hospital, Stony Brook, NY, ²⁰Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ²¹CRMO Patient Partner, Fort Collins, CO, ²²Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ²³Anna Meyer Children's Hospital, Firenze, Italy, ²⁴University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²⁵Georgetown University, DERWOOD, MD, ²⁶Tufts Medical Center, Boston, MA, ²⁷University of Iowa Carver College of Medicine, Iowa City, IA, ²⁸University of Liverpool, Liverpool, United Kingdom, ²⁹Boston Children's Hospital, Boston, MA, ³⁰Vivantes Children’s Hospital, Wuerzburg, Germany, ³¹The Hospital for Sick Children, Toronto, ON, Canada, ³²Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO) predominantly affects children and young adults. Classification criteria are not available and diagnostic criteria that have…
Abstract Number: 0801 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Joe Zhuo², Amy Schrader¹, Nicole Middaugh¹, Page Moore¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
Abstract Number: 1283 • ACR Convergence 2020
Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry
Clara Moriano¹, Jaime Calvo-Alén², Iñigo Rúa-Figueroa³, Elvira Díez Álvarez¹, Cristina Bermúdez⁴, Francisco J López-Longo⁵, Maria Galindo-Izquierdo⁶, Alejandro Olivé-Marqués⁷, Eva Tomero Muriel⁸, Antonio Fernandez-Nebro⁹, Mercedes Freire-González¹⁰, Olaia Fernandez-Berrizbeitia¹¹, Ana Pérez Gómez¹², Maria Esther Uriarte¹³, Carlos Marras Fernández-Cid¹⁴, Carlos Montilla Morales¹⁵, Gregorio Santos Soler¹⁶, Ricardo Blanco¹⁷, Manuel Rodríguez-Gómez¹⁸, Paloma Vela¹⁹, Alina Lucica Boteanu²⁰, Francisco Javier Narváez²¹, Victor Martinez Taboada²², Blanca Hernández Cruz²³, Jose Luis Andreu Sanchez²⁴, Jose A Hernández-Beriain²⁵, Lorena Expósito²⁶, Raul Menor Almagro²⁷, Mónica Ibañez-Barceló²⁸, Ivan Castellvi²⁹, Carlos Galisteo³⁰, Enrique Raya³¹, VE Quevedo-Vila³², Tomás Vázquez³³, J Ibáñez-Ruan³⁴ and Jose Maria Pego-Reigosa³⁵, ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁴Research Unit Bioaraba, Vitoria, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Germans Trias i Pujol, Barcelona, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ⁹University of Malaga, Malaga, Spain, ¹⁰CHU Coruña, Coruña, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Hospital Universitario Príncipe Asturias, Alcalá de Henares, Madrid, Spain, ¹³Hospital Universitario Donostia, San Sebastian, Spain, ¹⁴Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁵Hospital Universitario de Salamanca, Salamanca, Spain, ¹⁶Hospital Marina Baixa, Alicante, Spain, ¹⁷Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁸Hospital Complex of Ourense, Ourense, Spain, ¹⁹Hospital General Alicante, Alicante, Spain, ²⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²¹Hospital Bellvitge, BARCELONA, Spain, ²²Marqués de Valdecilla University Hospital, Santander, Spain, ²³Universidad de Sevilla, Sevilla, Spain, ²⁴Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Hospital Clinico Tenerife, Tenerife, Spain, ²⁷Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, ²⁸Hospital Son Llatzer, Mallorca, Spain, ²⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³⁰Hospital Parc Taulí, Barcelona, Spain, ³¹Hospital San Cecilio, Granada, Spain, ³²Hospital Comarcal de Monforte, Lugo, Spain, ³³Hospital Lucus Augusti, Lugo, Spain, ³⁴Hospital Povisa, Vigo, Pontevedra, Spain, ³⁵University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences.To analyze the causes…
Abstract Number: 0802 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness
Yoshiya Tanaka¹, Hisashi Yamanaka², Leslie Harrold³, Tin-chi Lin³, Ekta Agarwal⁴, Jose L Rivas⁵, Naonobu Sugiyama⁶, Jeffrey Greenberg⁷ and Mitsumasa Kishimoto⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ³Corrona, LLC, Waltham, MA, ⁴Pfizer, Inc., Princeton Jct, NJ, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Japan Inc, Tokyo, Japan, ⁷Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁸Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: There are several conventional synthetic, targeted synthetic and biological disease-modifying anti-rheumatic medications (DMARDs) approved for the treatment of rheumatoid arthritis (RA) in Japan. Little…
Abstract Number: 1335 • ACR Convergence 2020
Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Dominic Seet¹, Li Wearn Koh², Preeti Dhanasekaran³, Man Hua Aw⁴, Rosa Lim Mui San², Siaw Ing Yeo⁴ and Manjari Lahiri¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, Singapore, ⁴Singapore General Hospital, Singapore, Singapore
Background/Purpose: To describe the demographic and clinical characteristics of patients with inflammatory arthritis (IA) initiating biologic disease modifying anti-rheumatic drugs (bDMARD) who use complementary and…
Abstract Number: 0803 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety
Mitsumasa Kishimoto¹, Yoshiya Tanaka², Leslie Harrold³, Alina Onofrei³, Christine Barr⁴, Ekta Agarwal⁵, Jose L Rivas⁶, Naonobu Sugiyama⁷, Jeffrey Greenberg⁸ and Hisashi Yamanaka⁹, ¹Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Albany, NY, ⁵Pfizer, Inc., Princeton Jct, NJ, ⁶Pfizer SLU, Madrid, Spain, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁹Sanno Medical Center, Tokyo, Japan, Tokyo, Japan
Background/Purpose: There is limited information on the real-world safety of disease-modifying anti-rheumatic drugs (DMARDs) approved for treating rheumatoid arthritis (RA) in Japan. Using a Japanese…

1
2
3
…
7
Next Page »